Increasing prevalence of metastatic tumors and the demand for outpatient surgeries are expected to drive the global glioma diagnosis and treatment market during the forecast period, 2017–2023

Market Research Future (MRFR) announces the publication of its research report – Global Glioma Diagnosis and Treatment Market, 2017–2023

Market Synopsis

Brain tumors are one of the prominent causes of cancer among children and teenagers. Glioma is the most common type of brain tumor which accounts for approximately half of all the astrocytoma. The increasing occurrence of glioblastoma over the years is responsible for the growth of the glioma diagnosis and treatment market. The upcoming drug launches and developments in research are instrumental for the growth of the market. In addition, the current unmet need is expected to drive the gliomas industry over the forecast period. Changing financial demands and access to healthcare facilities are some of the factors that are constraining the market growth.

Market Segments:

Geographically, the Americas glioma diagnosis and treatment market is segmented into two major regions, namely, North America and South America.

North America accounted for the largest share of the global gliomas industry in 2016, and the trend is expected to continue over the projected period. Moreover, it is anticipated that about 80,000 new cases will be registered related to brain tumors in the year 2017 which includes 26,000 primary malignant brain tumors.

The Americas glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.

Access Report Details @ https://www.marketresearchfuture.com/reports/glioma-diagnosis-treatment-market-5877

On the basis of type, the global glioma diagnosis and treatment market is segmented into primary tumors and secondary tumors. The primary tumors are divided into ependymomas, astrocytomas, oligodendrogliomas, brainstem glioma, optic nerve glioma, mixed gliomas, and others.

The ependymomas segment is divided into subependymomas (grade i), myxopapillary ependymomas (grade i), ependymomas (grade ii), and anaplastic ependymomas (grade iii). The astrocytomas segment is divided into anaplastic astrocytomas, glioblastoma multiforme, and benign astrocytomas. The optic nerve glioma segment is divided into malignant optic nerve glioma and benign optic nerve glioma. The mixed gliomas are divided into oligoastrocytomas and others.

On the basis of diagnosis, the global glioma diagnosis and treatment market is classified into neurological exam, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scan, biopsy, molecular testing, Electroencephalography (EEG), and others.

On the basis of treatment, the global glioma diagnosis and treatment market is classified into surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. Furthermore, the surgery is further categorized into open surgery and minimally invasive surgery.

On the basis of grade, the global glioma diagnosis and treatment market is segmented into low-grade gliomas, high-grade gliomas, and recurrent high-grade glioma.

On the basis of location, the global glioma diagnosis and treatment market is segmented into supratentorial and infratentorial.

On the basis of end-user, the global glioma diagnosis and treatment market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.

The Americas market for glioma diagnosis and treatment is expected to grow at a CAGR of approximately ~7.0% during the forecast period, 2017–2023.

Key Players:

Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switzerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.